DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Anti-obesity drugs and weight-loss therapies
Scientific Comparison of Anti-Obesity Drug Efficacy 2025 – Complete Report Scientific Comparison of Anti-Obesity Drug Efficacy Semaglutide, Tirzepatide, Liraglutide, and Pemvidutide Complete Scientific Report – Updated: November 25, 2025 Table of Contents 1. Introduction 2. Mechanisms of Action and Pharmacological…
SYM Symbotic Inc
Symbotic surges +35% post-earnings; valuation tightens as growth investors price in upside
ADMA BIOLOGICS
ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033).
TNXP Tonix Pharmaceuticals
FDA APPROVED BUT HIGH DILUTION RISK
GME THE REDDIT REVOLUTION CONTINUES
GameStop [finance:GameStop Corp.] is not a typical stock—it is a cultural movement, a symbol of retail trader empowerment, and a battleground between Wall Street and Main Street. S
RIGL Rigel Pharmaceuticals Update Feb 2026
Rigel Pharmaceuticals [finance:Rigel Pharmaceuticals, Inc.] is a rare breed in biotech: profitable, cash-generative, and growth-oriented.
OSCR Oscar Health
oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary…
ENLV Enlivex Therapeutics
Enlivex Therapeutics [finance:Enlivex Therapeutics Ltd.] announced two simultaneous catalysts on November 23-24, 2025, triggering a 74% intraday spike to $1.59: (1) positive 6-month topline data from the Allocetra Phase IIa trial demonstrating durable pain reduction, and (2) a $212M PIPE financing at $1.00/share closing November 25. The clinical data supports Phase IIb progression, but the financing creates massive shareholder dilution (~99%) and introduces governance/crypto risks requiring careful assessment.
Weekly Market Analysis Nov 24
The major US stock indices closed the week of November 22 with significant losses, despite a Friday rebound.
ALT Altimmune, Inc.
Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases.
PLX Protalix Biotherapeutics
Protalix Biotherapeutics (NASDAQ: PLX) is an Israeli biotech company specializing in plant cell-expressed recombinant proteins using its proprietary ProCellEx platform.
OTLK Outlook Therapeutics, Inc.
Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).
Palatin Technologies Inc.
Palatin Technologies (NYSE American: PTN) is a micro-cap biotech specializing in obesity treatment through melanocortin-4 receptor (MC4R) agonists.
BCRX BioCryst Pharmaceuticals nov 21
Positive Pediatric Catalyst:
FDA approval on December 12 could represent a doubling of TAM (Total Addressable Market) by adding the completely underserved pediatric segment (zero approved oral therapies).
RGNX REGENXBIO
Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome).
Aldeyra Therapeutics dec 16 PDUFA
Aldeyra Therapeutics (ALDX) – Comprehensive PDUFA Report ?? ?? Aldeyra Therapeutics Ticker ALDX PDUFA Date December 16, 2025 Current Price ~$5.16 Report Date November 21, 2025 ? Executive Summary Aldeyra Therapeutics (ALDX) is approaching a pivotal catalyst: a binary FDA…
NVRI Enviri Corporation
Enviri Corporation Announces Sale of Clean Earth to Veolia for $3.04 Billion and Taxable Spin-Off of Harsco Environmental and Rail Businesses ("New Enviri") to Shareholders
MNDR Mobile-health Network Solutions
Mobile-health Network Solutions (MNDR) announced a non-binding MOU on November 19, 2025, to acquire two AI-optimized data centers in Malaysia valued up to $120 million.
Top 10 Healthcare Small-Caps Stocks
Top 10 Healthcare Small-Caps Stocks Nov '25
NUVB Oncology Breakout
?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator…